Volume 30, Number 12—December 2024
Research
Clinical Manifestations, Antifungal Drug Susceptibility, and Treatment Outcomes for Emerging Zoonotic Cutaneous Sporotrichosis, Thailand
Pattriya Jirawattanadon, Sumanas Bunyaratavej, Charussri Leeyaphan, Piriyaporn Chongtrakool, Panitta Sitthinamsuwan, Waratchaya Panjapakkul, Suthasanee Prasertsook, Phuwakorn Saengthong-aram, Nicha Wareesawetsuwan, Julaluck Posri, and Penvadee Pattanaprichakul
Table 3
Clinical manifestation comparisons between patients with and without cat exposure in study of clinical manifestations, antifungal drug susceptibility, and treatment outcomes for emerging zoonotic cutaneous sporotrichosis, Thailand*
| Demographic data | Cat exposure, n = 32 | No cat exposure, n = 17 | Univariate analysis |
Multivariate analysis† |
|||
|---|---|---|---|---|---|---|---|
| Crude OR (95% CI) | p value | Adjusted OR‡ (95% CI) | p value | ||||
| Patient sex | |||||||
| M | 9 (28.1) | 8 (47.1) | 2.3 (0.7–7.7) | 0.189 |
NA |
||
| F |
23 (71.9) |
9 (52.9) |
Referent |
||||
| Mean age, y (±SD) | 55.0 (±16.4) | 65.5 (±16.1) | 0.9 (0.9–1.0) | 0.084 | 1.0 (0.9–1.0) | 0.095 | |
| Median symptom duration, d (IQR) |
30.0 (21.0–83.0) |
30.0 (22.0–60.0) |
1.0 (0.9–1.0) |
0.916 |
NA |
||
| Immunologic status | |||||||
| Immunocompromised | 3 (9.4) | 6 (35.3) | 5.3 (1.1–24.8) | 0.036 | 5.2 (1.1–24.8) | 0.036 | |
| Immunocompetent | 29 (90.6) | 11 (64.7) | Referent | Referent | |||
| Sporotrichosis in family member, n = 47 |
5/32 (15.6) |
0/15 (0.0) |
NA |
0.162 |
NA |
||
| Lesions | |||||||
| Single | 9 (28.1) | 11 (64.7) | Referent | 0.016 |
Referent | 0.100 |
|
| Multiple |
23 (71.9) |
6 (35.3) |
4.7 (1.3–16.5) |
6.1 (0.9–24.4) |
|||
| Lesions site | |||||||
| Head and neck | 0 (0) | 3 (17.6) | NA | 0.073 | NA | ||
| Trunk | 0 (0.0) | 1 (5.9) | NA | 0.347 | NA | ||
| Upper extremities | 29 (90.6) | 7 (41.2) | 13.8 (3.0–63.9) | 0.001 | 18.9 (3.2–92.9) | 0.001 | |
| Lower extremities |
5 (15.6) |
6 (35.3) |
0.3 (0.1–1.4) |
0.125 |
NA |
||
| Morphology | |||||||
| Nonpustular | 23 (71.9) | 11 (64.7) | Referent | 0.605 |
NA |
||
| Pustular |
9 (28.1) |
6 (35.3) |
0.7 (0.2–2.5) |
||||
| Arrangement | |||||||
| Lymphocutaneous pattern | 18 (56.3) | 4 (23.5) | 4.2 (1.1–15.7) | 0.034 | 3.7 (0.8–16.7) | 0.093 | |
| Lymphadenopathy, n = 44 |
3/28 (10.7) |
3/16 (18.8) |
0.5 (0.1–3.0) |
0.460 |
|||
| Median treatment duration, d (IQR) | |||||||
| Until improvement | 46.0 (30.0–107.0) | 53.0 (30.0–90.0) | 1.0 (0.9–1.0) | 0.625 | NA | ||
| Until cured | 183.0 (135.0–246.0) | 165.0 (136.0–206.0) | 1.0 (0.9–1.0) | 0.495 | NA | ||
*Values are no. patients/total no. patients (%) except as indicated. Bolded numbers are significant p values <0.05. IQR, interquartile range; NA, not applicable; OR, odds ratio. Multivariate analysis was conducted by using multiple binary logistic regression. ‡Adjusted for patient sex and age.
Page created: September 24, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.